Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial

Juan P. Frías, Pernille Auerbach, Harpreet S. Bajaj, Yasushi Fukushima, Ildiko Lingvay, Stanislava Macura, Anette L. Søndergaard, Tsvetalina I. Tankova, Nikolaos Tentolouris, John B. Buse

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial'. Together they form a unique fingerprint.

Medicine & Life Sciences